Exelixis Inc

Exelixis Inc. stock surges on strong Q1 performance, with analysts raising price targets and the company increasing revenue guidance, driven by robust sales of its flagship cancer treatment, Cabometyx.

Exelixis Inc. reported a 31% increase in revenue for Q1 2025, driven by strong sales of CABOMETYX, leading to raised full-year revenue guidance and increased stock price targets from analysts.

Exelixis Inc. exceeded first-quarter profit expectations, sending its stock surging and leaving investors optimistic about the company’s future prospects in the biotech industry.

Exelixis Inc. shares surged as the biotech company reported a Q1 profit that exceeded market expectations, solidifying its position as a leader in the sector.